General Information of Drug (ID: DM6MEX4)

Drug Name
CGS-12066B Drug Info
Synonyms
CGS 12066B; UNII-5TB4SXQ7HG; CGS 12066B-parent; Cgs 12066; CGS12066; 5TB4SXQ7HG; 109028-09-3; 4-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)pyrrolo[1,2-a]quinoxaline; CHEMBL27403; CGS-12066B; CHEBI:64055; CGS-12066A; CGS-12066; CGS-12066A maleate salt; Pyrrolo[1,2-a]quinoxaline, 4-(4-methyl-1-piperazinyl)-7-(trifluoromethyl)-; Pyrrolo(1,2-a)quinoxaline, 4-(4-methyl-1-piperazinyl)-7-(trifluoromethyl)-; NCGC00024701-01; Tocris-0638; 7-Trifluoromethyl-4-(4-methyl-1-piperazinyl)pyrrolo-[1,2-a]quinoxaline maleate salt
Indication
Disease Entry ICD 11 Status REF
Anxiety disorder 6B00-6B0Z Terminated [1]
Cross-matching ID
PubChem CID
9915956
CAS Number
CAS 109028-10-6
TTD Drug ID
DM6MEX4

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting 5-HT 1B receptor (HTR1B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [3]
Eletriptan DMW649X Migraine 8A80 Approved [4]
Zolmitriptan DM1IB4Q Migraine 8A80 Approved [4]
Frovatriptan DM7RE8P Migraine 8A80 Approved [4]
Fluphenazine DMIT8LX Psychotic disorder 6A20-6A25 Approved [4]
Naratriptan DMO50U2 Headache 8A80-8A84 Approved [5]
Prolixin decanoate DMMJ1IS Schizophrenia 6A20 Approved [4]
Eltoprazine DMW6C81 Attention deficit hyperactivity disorder 6A05.Z Phase 3 [6]
NXN-188 DMMBAIH Migraine 8A80 Phase 2 [7]
[N-methyl-3H(3)]AZ-10419369 DMSCV02 Mood disorder 6A60-6E23 Phase 1 [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 1B receptor (HTR1B) TTK8CXU 5HT1B_HUMAN Modulator [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 109).
2 Biochemical and pharmacological characterization of CGS 12066B, a selective serotonin-1B agonist. Eur J Pharmacol. 1987 Apr 7;136(1):1-9.
3 Two amino acid differences in the sixth transmembrane domain are partially responsible for the pharmacological differences between the 5-HT1D beta and 5-HT1E 5-hydroxytryptamine receptors. J Neurochem. 1996 Nov;67(5):2096-103.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5 Triptans in pregnancy. Ther Drug Monit. 2008 Feb;30(1):5-9.
6 Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
7 Company report (NeurAxon)
8 5-HT1B and other related serotonergic proteins are altered in APPswe mutation. Neurosci Lett. 2015 May 6;594:137-43.